NCT05614310Recruiting
Detecting Early Alzheimer's Using MR
Early Detection Of Alzheimer's Disease With GlucoCEST MRI: A Feasibility Study.
Source: ClinicalTrials.gov · Last updated 30 Mar 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
Alzheimer's disease (AD) is the most common cause of dementia, affecting approximately 10% of individuals aged ≥ 65. Most available treatments aim at controlling symptoms at an early stage rather than providing a cure. Therefore, an accurate and early diagnosis of AD with appropriate management will slow the progression of the condition. Reduced cerebral glucose levels have been observed in patients with early AD. Glucose hypometabolism can be assessed by administering a radioactive glucose analogue, 2-deoxy-2-(18F) fluoro-D-glucose (18FDG), and imaging with PET (positron emission tomography). The high cost and limited availability of PET-CT (PET - computed tomography) still hamper its general clinical application. Moreover, the use of radioactive tracers in combination with the additional ionizing radiation of CT is not suitable for repeated measurements. Therefore, currently, the provisional diagnosis of AD is still based on the combination of clinical history, neurological examination, cognitive testing over a period of time, and structural neuroimaging. This has major time and resource implications. A radically different and highly innovative means for imaging glucose with magnetic resonance imaging (MRI) has now been established, exploiting the interaction between hydroxyl protons in glucose and the protons in water; the method is termed glucose Chemical Exchange Saturation Transfer (glucoCEST). GlucoCEST MRI is a method that has no reliance on radiolabelled glucose analogues and could become widely implemented in clinic practice. We therefore aim to investigate the potential of glucoCEST MRI in Alzheimer's disease.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 60 (estimated)
- First submitted
- 3 Nov 2022
- Start date
- 15 Nov 2022
- Primary completion date
- 31 Dec 2025
- Lead sponsor
- University of Aberdeen
- Diseases
- Alzheimer disease
- NCT number
- NCT05614310
What you commit to
- Study type: Observational
- Planned participants: 60
- From 15 Nov 2022 to the primary completion date, 31 Dec 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- have a history of diabetes,
- have history of a major stroke (mini-stroke/Transient Ischaemic Attacks or lacunar stroke are acceptable),
- have contra-indications to MRI scanning such as implantable cardiac devices
Other
- Subjects will not be considered if they:
- have family history in AD, to exclude possible gene mutations associated with AD
- have advanced AD who lack the capacity to consent.
- Are pregnant (for developmental phase)
- are unable to read or speak English
Who the study is looking for
- Development phase:
- Controls (development group) must:
- be \> 18 years
- consent to the study
- not report problems with memory.
- Clinical phase
- Patients must:
- be ≥ 65 years,
- able to provide informed consent to the study
- have been clinically diagnosed with AD by the mental health team.
- Controls must:
- be ≥ 65 years
- able to provide consent to the study
- have a normal score in the ADAS-cog test and the Mini Mental State Examination test (MMSE)
- not report problems with memory.
Age in the registry: 18 years to - · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of Aberdeen Coordinator of this site? Confirm its status | Aberdeen | United Kingdom | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.